ProShare Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

ProShare Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$252K	Sell	18,154 -2,914	-14%	-$41K	﹤0.01%	1430
2025 Q4	$255K	Buy	21,068 +6,030	+40%	+$81.9K	﹤0.01%	1559
2025 Q3	$204K	Sell	15,038 -2,513	-14%	-$23.7K	﹤0.01%	1688
2025 Q2	$113K	Buy	+17,551	New	+$85.4K	﹤0.01%	1856
2024 Q3	–	Sell	-11,000	Closed	-$20.9K	–	2067
2024 Q2	$20.9K	Sell	11,000 -2,874	-21%	-$5.57K	﹤0.01%	1808
2024 Q1	$39.4K	Buy	13,874 +1,153	+9%	+$15.1K	﹤0.01%	1932
2023 Q4	$187K	Buy	12,721 +1,715	+16%	+$26.3K	﹤0.01%	1656
2023 Q3	$202K	Buy	11,006 +54	+0.5%	+$1.14K	﹤0.01%	1460
2023 Q2	$236K	Buy	10,952 +424	+4%	+$11.5K	﹤0.01%	1434
2023 Q1	$309K	Sell	10,528 -1,440	-12%	-$50K	﹤0.01%	1199
2022 Q4	$442K	Buy	+11,968	New	+$425K	﹤0.01%	1020

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

ProShare Advisors's AMLX Position: Q1 2026 in Review

ProShare Advisors reduced its Amylyx Pharmaceuticals (AMLX) stake by 14% in Q1 2026, selling an estimated $41K and leaving 18,154 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #1430.

ProShare Advisors first reported a position in AMLX in Q4 2022 and has held it in 11 quarters since. The position peaked at $442K in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

ProShare Advisors held 18,154 shares of Amylyx Pharmaceuticals worth $252K as of Q1 2026.
ProShare Advisors sold 2,914 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $41K.
Amylyx Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1430 holding.
ProShare Advisors first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
ProShare Advisors's Amylyx Pharmaceuticals position peaked at $442K in Q4 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.